All Stories

  1. How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?

    Article • Diabetes, February 2021, American Diabetes Association

    Michael Haller

  2. Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report

    Article • Diabetes, February 2021, American Diabetes Association

    Michael Haller

  3. Low-Dose ATG Preserves Beta Cell Function and Reduced A1c 2 Years After Therapy

    Article • Diabetes, April 2019, American Diabetes Association

    Michael Haller

  4. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1cin New-Onset Type 1 Diabetes

    Article • Diabetes Care, July 2018, American Diabetes Association

    Michael Haller